Argenx
ARGX
#419
Rank
$56.12 B
Marketcap
$901.17
Share price
-1.62%
Change (1 day)
47.49%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2025 (TTM): $8.87

According to Argenx 's latest financial reports the company's current EPS (TTM) is $8.87. In 2024 the company made an earnings per share (EPS) of $13.92 an increase over its 2023 EPS that were of -$5.16.

EPS history for Argenx from 2011 to 2025

Annual EPS

Year EPS Change
2025 (TTM)$8.87-36.28%
2024$13.92-369.77%
2023-$5.16-60.46%
2022-$13.0563.33%
2021-$7.99-40.37%
2020-$13.40183.47%
2019-$4.73123.09%
2018-$2.1254.93%
2017-$1.3714.07%
2016-$1.2013.05%
2015-$1.06-36.34%
2014-$1.67209.04%
2013-$0.54-33.99%
2012-$0.82185.59%
2011-$0.29